Home > Boards > US Listed > Biotechs >

Inovio Biomedical Corp. (INO)

Add INO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator subslover, OceanEagle1, pistol1p, kablahm, biovalidator
Search This Board:
Last Post: 7/24/2014 4:11:28 PM - Followers: 395 - Board type: Free - Posts Today: 13

Logo: Inovio




ebruary 12, 2014 Inovio CEO Dr. Joseph Kim rings bell to open trading on NYSE- http://www.youtube.com/watch?v=95yO6hFpbUM

Float: 97.65 M

Shares Outstanding: 127.26 M

Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company?s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio?s proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio?s clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Roche,Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005. The company was founded in 1983 and is based in San Diego, California.

Currently Inovio has 12 clinical studies ( HIV, Influenza, Malaria, Hepatitis B, Hepatitis C, Breast and Lung cancer, Prostate Cancer, Head and Neck cancer, Cervical Cancer, Cervical dysplasia caused by HPV) ongoing from preclinical to phase 2.
Sep 10, 2013
Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products. Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&D support and payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche pursues other indications with INO-5150 or INO-1800.  In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales.

VGX-3100-Phase 2 Clinical Trial initiated for the treatment Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV
Top line data release Mid 2014
May 13, 2014:  Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis

May 23, 2014: Inovio Pharmaceuticals Announces 1 For 4 Reverse Split
1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.

Inovio’s goal is to revolutionize vaccines. With best-in-class immune responses from multiple vaccines in different disease areas, our synthetic vaccine technology is making big strides toward this important goal.



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
INO News: Securities Registration Statement (simplified Form) (s-3) 07/23/2014 04:33:27 PM
INO News: Current Report Filing (8-k) 07/23/2014 01:07:25 PM
INO News: Current Report Filing (8-k) 07/23/2014 09:21:19 AM
INO News: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 07/23/2014 09:15:00 AM
INO News: Inovio Pharmaceuticals Added To Russell Global, Russell 2000® and Russell Microcap® Indexes 07/01/2014 04:00:00 AM
#11886  Sticky Note INOVIO RESPONDS - FRESH OFF THE PRESS - CCruzNY 06/11/14 09:10:07 AM
#11802  Sticky Note New ino Article http://m.seekingalpha.com/article/2259253-too-many-pending-mile Fsa888 06/09/14 12:54:48 PM
#4698  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 08/02/13 01:15:33 PM
#12293   Even Motley Fool is on board Rule_62 07/24/14 04:11:28 PM
#12292   Stock split opinion. future1 07/24/14 12:06:13 PM
#12291   http://www.theflyonthewall.com/permalinks/entry.php/INOid2043339/INO-Inovio cracity 07/24/14 11:54:21 AM
#12290   Aegis Capital raises price target to $19 (from CHM_760 07/24/14 11:21:58 AM
#12289   I added 20k shares yesterday. I agree DrBob99 07/24/14 11:18:45 AM
#12288   Anybody buying today, besides me? pistol1p 07/24/14 10:44:29 AM
#12286   You may find this helpful.. kablahm 07/24/14 08:37:26 AM
#12285   The S3 is only for the SHELF and one_would_believe 07/24/14 05:08:56 AM
#12284   It was stated 2 years. nypete 07/24/14 04:04:12 AM
#12283   Anyone have any idea how long the phase Dynarod 07/24/14 01:54:55 AM
#12282   Dr kim had say it before that if cwwan1 07/24/14 01:37:19 AM
#12281   Speaking of "The Street" thugs, I used to Rule_62 07/24/14 01:18:44 AM
#12280   Also a buying opportunity? pistol1p 07/23/14 10:44:48 PM
#12279   Everywhereman, I do appreciate all the information and expertise pistol1p 07/23/14 10:21:16 PM
#12278   Couldn't agree more, $INO is really shaping up kablahm 07/23/14 09:18:03 PM
#12277   I have faith in this stock and have 7777777777 07/23/14 09:17:09 PM
#12276   Still undervalued here? kablahm 07/23/14 08:24:39 PM
#12275   Yeah Pat..........you and I both. I remember speculating johan31 07/23/14 08:03:28 PM
#12274   These guys are geniuses, and I don't question mrpatinmn 07/23/14 07:42:36 PM
#12273   Wonder if this is to do the P3 alone? imtheking 07/23/14 07:39:21 PM
#12272   I agree completely.....no reason to do it so johan31 07/23/14 07:07:00 PM
#12271   From the Facebook INO page - DrBob99 07/23/14 06:17:05 PM
#12270   Look back at past PRs from Inovio. DrBob99 07/23/14 06:05:33 PM
#12269   I've always believed this was a planned 1-2 Autumnforest 07/23/14 06:02:50 PM
#12268   I don't really have a real good reason Quanic Buds 07/23/14 06:01:59 PM
#12267   I think that this is part of a DrBob99 07/23/14 05:55:44 PM
#12266   Agreed! Why do it so soon after an Quanic Buds 07/23/14 05:36:51 PM
#12265   Why now? CHM_760 07/23/14 05:30:36 PM
#12264   Wow, they couldn't even let us enjoy good ImaPseudonym 07/23/14 05:26:33 PM
#12263   S-3 Mixed Shelf Filed CHM_760 07/23/14 04:48:56 PM
#12262   POS INO that's why don't like to hold overnight spades 07/23/14 04:39:17 PM
#12261   Thanks for the updates. Can you provide any plain_ole_pain 07/23/14 04:21:55 PM
#12260   INO 13 looks like it was setting up spades 07/23/14 03:35:45 PM
#12259   Ima, Thanks for the explanation. someconcerns 07/23/14 02:45:12 PM
#12258   This was pretty much expected. It is precisely ImaPseudonym 07/23/14 02:40:09 PM
#12257   It is great that there was a statistically-significant someconcerns 07/23/14 02:35:24 PM
#12256   Please tell Dr. Kim that he is a DrBob99 07/23/14 02:12:09 PM
#12255   Dr. Kim's latest presentation is now up on johan31 07/23/14 02:04:03 PM
#12254   Guys we should all take a moment of Everywhereman 07/23/14 02:02:37 PM
#12253   8k filed!! Regulation fd disclosure Fsa888 07/23/14 01:56:07 PM
#12252   Thanks very much! CHM_760 07/23/14 01:50:40 PM
#12251   Here you go: ImaPseudonym 07/23/14 01:48:57 PM
#12250   Might be due to Maxim's $18 target. CHM_760 07/23/14 01:33:27 PM
#12249   $INO VGX-3100 Represents A Completely New Treatment Paradigm maytepper 07/23/14 01:33:23 PM
#12248   Any away we go.... About to break 13 again! DrBob99 07/23/14 01:30:36 PM
#12247   Glad to see that Dr Kim is keeping CHM_760 07/23/14 01:16:31 PM
#12246   Just filed an 8k with the SEC for ImaPseudonym 07/23/14 01:12:44 PM
#12245   The best catalyst for INO to end the future1 07/23/14 01:01:56 PM
#12244   I don't know, that's why I was just ImaPseudonym 07/23/14 12:55:59 PM
#12243   what's the difference between clearing the virus and mrpatinmn 07/23/14 12:45:49 PM